Table 1.
Clinico-pathological features on 30 patients in this study
| Age (yr) | |
|---|---|
| Median (Range) |
60 (33—72) |
| Gender: n (%) | |
| Male |
27 (90.0%) |
| Female |
3 (10.0%) |
| Gastric cancer site: n (%) | |
| Gastric antrum |
11 (36.7%) |
| Gastric body |
9 (30.0%) |
| Gastric cardia-fundus |
10 (33.3%) |
| Elevated tumor markers: n (%) | |
| CEA |
7 (23.3%) |
| AFP |
6 (20.0%) |
| CA19-9 |
8 (26.7%) |
| Gastric cancer diameter: cm | |
| Median (Range) |
3.7 (1.0—11.0) |
| Pathological type: n (%) |
|
| Papillary adenocarcinoma |
13 (43.3%) |
| Tubular adenocarcinoma |
10 (33.3%) |
| Poorly differentiated adenocarcinoma |
4 (13.3%) |
| Mucinous adenocarcinoma |
3 (10.0%) |
| Number of intrahepatic metastases: n (%) | |
| Single metastastic lesion |
22 (73.3%) |
| Multiple metastatic lesions |
8 (26.7%) |
| Diameter of intrahepatic metastasis lesions: cm | |
| Median (Range) |
3.1 (0.5—16.0) |
| Surgical approaches: n (%) | |
| Distal gastrectomy |
11 (36.7%) |
| Total gastrectomy |
9 (30.0%) |
| Proximal gastrectomy |
10 (33.3%) |
| T classification: n(%) |
|
| T1 |
1 (3.3%) |
| T2 |
3 (10.0%) |
| T4a |
26 (86.7%) |
| N classification: n (%) |
|
| N0 |
7 (23.3%) |
| N1 |
3 (10.0%) |
| N2 |
5 (16.7%) |
| N3 |
15 (50.0%) |
| Peritoneal metastasis |
|
| P0 |
25 (83.3%) |
| P1 |
5 (16.7%) |
| Tumor embolus |
|
| Yes |
13 (43.3%) |
| No |
17 (56.7%) |
| Tumor differentiation: n (%) |
|
| Well differentiated |
2 (6.67%) |
| Intermediately differentiated |
5 (16.7%) |
| Poorly differentiated |
23 (76.7%) |
| Survival status: n (%) |
|
| Survived |
5 (16.7%) |
| Died | 25 (83.3%) |